Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 1
---
 and will not receive any of the proceeds from the sale of the Depositary Shares by the Selling Shareholder. Additionally, we will not receive any proceeds from the issuance or sale of the Commitment Shares, if issued to release the Company of its liability to pay the Commitment Fee (as defined herein). However, we may receive up to $35.0 million in aggregate gross proceeds fromthe Selling Shareholder under the Purchase Agreement in connection with sales of Depositary Shares tothe Selling Shareholder pursuant to the Purchase Agreement after the date of this prospectus. The purchase price per Depositary Share thatthe Selling Shareholder
will pay for Depositary Shares purchased from us under the Purchase Agreement will fluctuate based on the market price of our Depositary Shares at the time we elect to sell shares tothe Selling Shareholder and, further, to the extent that we sell Depositary Shares under the Equity Financing, substantial amounts of Depositary Shares could be issued and resold, which would cause dilution and may impact our stock price.

This prospectus provides you
with a general description of such securities and the general manner in which the Selling Shareholder may offer or sell the securities.
More specific terms of any securities that the Selling Shareholder may offer or sell may be provided in a prospectus supplement that describes,
among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement
may also add, update or change information contained in this prospectus.

The Selling Shareholder may
offer, sell or distribute all or a portion of the Depositary Shares acquired under the Purchase Agreement and hereby registered publicly
or through private transactions at prevailing market prices or at negotiated prices. We will bear all costs, expenses and fees in connection
with the registration of the Depositary Shares, including with regard to compliance with state securities or “blue sky” laws.
The timing and amount of any sales are within the sole discretion of the Selling Shareholder. The Selling Shareholder is an underwriter
under the Securities Act of 1933, as amended, with respect to the resale of shares held by it. Although the Selling Shareholder is obligated
to purchase Depositary Shares under the terms and subject to the conditions and limitations of the Purchase Agreement to the extent we
choose to sell such Depositary Shares to it (subject to certain conditions), there can be no assurances that we will choose to sell any
Depositary Shares to the Selling Shareholder, or that the Selling Shareholder will sell any or all